Tenosynovial giant cell tumours of the foot and ankle: a retrospective single centre experience with surgical treatment of 34 cases

被引:0
作者
Scheele, Christian [1 ]
Harrasser, Norbert [1 ]
Beischl, Simone [1 ]
Dammerer, Dietmar [2 ]
Lenze, Ulrich [1 ]
Knebel, Carolin [1 ]
von Eisenhart-Rothe, Ruediger [1 ]
Lenze, Florian [1 ]
Scheele, Christian. B. [1 ]
机构
[1] Tech Univ Munich, Dept Orthopaed & Sports Orthopaed, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany
[2] Krems Univ Hosp, Dept Orthopaed & Traumatol, A-3500 Krems, Austria
关键词
TGCT; Tenosynovial giant cell tumour; PVNS; Pigmented villonodular synovitis; Soft-tissue tumour; Foot; Ankle; PIGMENTED VILLONODULAR SYNOVITIS; TENDON SHEATH; DIFFUSE; KNEE; EXCISION; OUTCOMES; RISK;
D O I
10.1186/s12885-025-13921-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTenosynovial giant cell tumour (TGCT) is one of the most prevalent soft tissue tumours of the foot and ankle. Although typically benign, it can exhibit locally aggressive behaviour. This study aims to evaluate the distribution, surgical management, and recurrence rates of localized (L-TGCT) and diffuse (D-TGCT) forms of TGCT.MethodsA retrospective study of 34 TGCT cases in the foot and ankle treated surgically between 2010 and 2023 was conducted. Inclusion criteria required a histologically confirmed diagnosis and a minimum potential follow-up period of 18 months. Patient demographics, radiological findings, surgical approach and recurrence rates were evaluated.ResultsOf 34 cases, 61.8% were L-TGCT and 38.2% were D-TGCT. L-TGCT had a significantly shorter duration of symptoms (median: 6 months) than D-TGCT (36 months, p = 0.01) and affected significantly more females (76.2%; p = 0.013). Nineteen cases were intraarticular, and 15 cases extraarticular manifestationsMacroscopically complete resection was achieved in 95.2% of L-TGCT cases and 69.2% of D-TGCT cases (p = 0.037). The recurrence rate with limited follow-up was 26.7% for L-TGCT and 50.0% for D-TGCT (p = 0.263). Time to recurrence was 7.0 months for L-TGCT and 12.0 months for D-TGCT (p = 0.287). In 40% of these cases, therapeutic intervention was performed.ConclusionIn the foot and ankle, L-TGCT is more common in females, presents earlier after symptom onset, and has a higher rate of complete resection, whereas D-TGCT has a longer symptom duration and higher recurrence rates. It's important for orthopaedic surgeons to weigh surgical margins against functional results, as stable outcomes appear to be attainable even in cases of residual or recurrent tumours.
引用
收藏
页数:8
相关论文
共 55 条
[1]   Benign synovial disorders [J].
Adelani, Muyibat A. ;
Wupperman, Richard M. ;
Holt, Ginger E. .
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, 2008, 16 (05) :268-275
[2]   Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle [J].
Barnett, James Robert ;
Rudran, Branavan ;
Khan, Amir ;
O'Reilly-Harbidge, Sarah ;
Patel, Shelain ;
Malhotra, Karan ;
Cullen, Nicholas ;
Welck, Matthew ;
Aston, William .
FOOT & ANKLE INTERNATIONAL, 2023, 44 (10) :1013-1020
[3]   Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis) [J].
Bertoni, F ;
Unni, KK ;
Beabout, JW ;
Sim, FH .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (02) :153-163
[4]  
Bisbinas Ilias, 2004, J Foot Ankle Surg, V43, P407
[5]   Pigmented villonodular synovitis of the foot and ankle [J].
Brien, EW ;
Sacoman, DM ;
Mirra, JM .
FOOT & ANKLE INTERNATIONAL, 2004, 25 (12) :908-913
[6]  
BYERS P D, 1968, Journal of Bone and Joint Surgery British Volume, V50, P290
[7]   Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy [J].
Cannarile, Michael A. ;
Weisser, Martin ;
Jacob, Wolfgang ;
Jegg, Anna-Maria ;
Ries, Carola H. ;
Ruettinger, Dominik .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[8]   CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study [J].
Cassier, Philippe A. ;
Italiano, Antoine ;
Gomez-Roca, Carlos A. ;
Le Tourneau, Christophe ;
Toulmonde, Maud ;
Cannarile, Michael A. ;
Ries, Carola ;
Brillouet, Anne ;
Mueller, Claudia ;
Jegg, Anna-Maria ;
Broeske, Ann-Marie ;
Dembowski, Markus ;
Bray-French, Katharine ;
Freilinger, Christine ;
Meneses-Lorente, Georgina ;
Baehner, Monika ;
Harding, Ross ;
Ratnayake, Jayantha ;
Abiraj, Keelara ;
Gass, Nathalie ;
Noh, Karen ;
Christen, Randolph D. ;
Ukarma, Lidia ;
Bompas, Emmanuelle ;
Delord, Jean-Pierre ;
Blay, Jean-Yves ;
Ruettinger, Dominik .
LANCET ONCOLOGY, 2015, 16 (08) :949-956
[9]   Villonodular synovitis of the ankle. Analysis of the risk of recurrence [J].
Cattelan, M. ;
Bonnomet, F. ;
Bierry, G. ;
Di Marco, A. ;
Brinkert, D. ;
Adam, P. ;
Ehlinger, M. .
ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH, 2016, 102 (05) :639-644
[10]   Tenosynovial giant cell tumor in the foot and ankle [J].
Cevik, Huseyin Bilgehan ;
Kayahan, Sibel ;
Eceviz, Engin ;
Gumustas, Seyit Ali .
FOOT AND ANKLE SURGERY, 2020, 26 (06) :712-716